- Arrowhead Pharmaceuticals has released two-year open-label extension data showing that investigational plozasiran delivered durable triglyceride reductions and a consistent safety profile in patients with severe and mixed hypertriglyceridemia, with no adjudicated acute pancreatitis events reported.
- The results underscore plozasiran’s potential to address a patient population with few effective long-term options by achieving triglyceride levels below guideline risk thresholds in most participants.
- We’ll now examine how this long-term safety and efficacy signal for plozasiran may influence Arrowhead’s investment narrative and risk profile.
Find 61 companies with promising cash flow potential yet trading below their fair value.
Arrowhead Pharmaceuticals Investment Narrative Recap
To own Arrowhead, you generally need to believe that RNAi can become a meaningful, multi-product business and that plozasiran is central to that story. The new two-year plozasiran data strengthen the program’s clinical profile, but the key near term swing factor remains the upcoming Phase 3 readouts and regulatory milestones, while the biggest risk is still that any late stage setback for plozasiran or other core assets could quickly change the revenue outlook.
The most directly relevant recent announcement is Arrowhead’s plan to complete the SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 plozasiran trials in mid 2026, with a planned U.S. filing by year end 2026. The fresh long term data in broader hypertriglyceridemia now sit alongside those timelines, giving investors more context as they weigh plozasiran’s role in Arrowhead’s potential transition from primarily milestone-driven revenue toward a more product-based model.
Yet, against this promising backdrop, investors should also be aware that regulatory or late stage clinical surprises could still...
Read the full narrative on Arrowhead Pharmaceuticals (it's free!)
Arrowhead Pharmaceuticals’ narrative projects $398.8 million revenue and $64.0 million earnings by 2028.
Uncover how Arrowhead Pharmaceuticals' forecasts yield a $64.08 fair value, a 11% upside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts were assuming revenue could fall about 49 percent a year and still only reach US$77.9 million by 2028, so compared with the more balanced risk of partner or trial setbacks, their view highlights how sharply opinions can diverge and why new long term data on plozasiran might eventually shift those expectations.
Explore 2 other fair value estimates on Arrowhead Pharmaceuticals - why the stock might be worth just $64.08!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Arrowhead Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
- Our free Arrowhead Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arrowhead Pharmaceuticals' overall financial health at a glance.
Contemplating Other Strategies?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- Uncover the next big thing with 30 elite penny stocks that balance risk and reward.
- Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com